Arbutus Biopharma (ABUS) Profit After Tax (2013 - 2026)

Arbutus Biopharma (ABUS) has reported Profit After Tax for 14 consecutive years, with $169.7 million the latest figure, recorded in Q1 2026.

• Quarterly Profit After Tax rose 791.02% year-over-year to $169.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.7 million (up 309.81% YoY) and the FY2025 annual result came in at -$33.5 million, up 52.09% from the prior year.
• Profit After Tax improved to $169.7 million in Q1 2026 per ABUS's latest filing, from -$3.8 million in the prior quarter.
• Over the last five years, Profit After Tax for ABUS reached as high as $169.7 million in Q1 2026 and fell as low as -$24.6 million in Q1 2025.
• A 5-year average of -$4.5 million and a median of -$17.1 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2025 — Profit After Tax sank 37.38% — and 2026, when it jumped 791.02%.
• Year by year, Profit After Tax stood at -$21.4 million in 2022, then rose by 9.82% to -$19.3 million in 2023, then soared by 35.11% to -$12.5 million in 2024, then jumped by 70.03% to -$3.8 million in 2025, then jumped by 4617.97% to $169.7 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $169.7 million, -$3.8 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.